Top

Current Hepatology Reports

Published in:

Open Access 01-12-2020 | Hepatitis B | Hepatitis B (JK Lim, Section Editor)

Chronic Hepatitis B and HIV Coinfection: a Continuing Challenge in the Era of Antiretroviral Therapy

Author: H. Nina Kim

Published in: Current Hepatology Reports | Issue 4/2020

Abstract

Purpose of Review

The burden of chronic hepatitis B (HBV) remains disproportionately high among people living with HIV (PLWH) despite the advent of HBV vaccination and HBV-active antiretroviral therapy (ART). This review summarizes new insights and evolving issues in HIV-HBV coinfection.

Recent Findings

HBV-HIV coinfection is still a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and liver-related mortality more than a decade after the approval of tenofovir. While tenofovir-based ART has been shown to improve rates of HBV virologic suppression and halt fibrosis progression, the long-term benefits on the prevention of end-stage liver disease or HCC in HIV-HBV coinfection have yet to be convincingly demonstrated in PLWH. Missed opportunities for HBV vaccination persist despite evidence of ongoing risk for HBV infection in this population.

Summary

Even as we work towards HBV elimination and functional cure, ongoing efforts should focus on optimizing risk stratification as well as uptake of HBV-active antiviral therapy and HBV immunization in this priority population.

• World Health Organization. Global hepatitis report, 2017. https://www.who.int/publications-detail-redirect/global-hepatitis-report-2017 (accessed Jul 1, 2020). This landmark report describes, for the first time, how viral hepatitis has emerged as a major public health threat globally and why a coordinated response is urgently needed.

• Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, et al. Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis. J Viral Hepat. 2020;27:294–315. https://doi.org/10.1111/jvh.13217This major systematic review provides regional and country estimates of the prevalence of chronic hepatitis B among PLWH across multiple subpopulations of interest.CrossRefPubMed

Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection--a global challenge. N Engl J Med. 2012;366:1749–52. https://doi.org/10.1056/NEJMp1201796.CrossRefPubMedPubMedCentral

Chun HM, Fieberg AM, Hullsiek KH, Lifson AR, Crum-Cianflone NF, Weintrob AC, et al. Epidemiology of hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50:426–36. https://doi.org/10.1086/649885.CrossRefPubMedPubMedCentral

Spradling PR, Richardson JT, Buchacz K, Moorman AC, Brooks JT, HIV Outpatient Study (HOPS) Investigators. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996-2007. J Viral Hepat. 2010;17:879–86. https://doi.org/10.1111/j.1365-2893.2009.01249.x.CrossRefPubMed

Roberts H, Kruszon-Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology. 2016;63:388–97. https://doi.org/10.1002/hep.28109.CrossRefPubMed

Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol. 2006;44:S65–70. https://doi.org/10.1016/j.jhep.2005.11.015.CrossRefPubMed

Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29:1306–10. https://doi.org/10.1002/hep.510290447.CrossRefPubMed

Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6. https://doi.org/10.1016/s0140-6736(02)11913-1.CrossRefPubMed

10.

Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: no longer a difficult-to-treat population. Hepatology. 2018;67:847–57. https://doi.org/10.1002/hep.29642.CrossRefPubMed

11.

AASLD/IDSA. Patients with HIV/HCV coinfection. Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org/unique-populations/hiv-hcv (accessed Jul 2, 2020).

12.

Falade-Nwulia O, Seaberg EC, Rinaldo CR, Badri S, Witt M, Thio CL. Comparative risk of liver-related mortality from chronic hepatitis B versus chronic hepatitis C virus infection. Clin Infect Dis. 2012;55:507–13. https://doi.org/10.1093/cid/cis432.CrossRefPubMedPubMedCentral

13.

Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, et al. Risk of end-stage liver disease in HIV-viral hepatitis coinfected persons in North America from the early to modern antiretroviral therapy eras. Clin Infect Dis. 2016;63:1160–7. https://doi.org/10.1093/cid/ciw531.CrossRefPubMedPubMedCentral

14.

Thornton AC, Jose S, Bhagani S, Chadwick D, Dunn D, Gilson R, et al. Hepatitis B, hepatitis C, and mortality among HIV-positive individuals. AIDS. 2017;31:2525–32. https://doi.org/10.1097/QAD.0000000000001646.CrossRefPubMedPubMedCentral

15.

Dienstag JL. Hepatitis B virus infection. N Engl J Med. 2008;359:1486–500. https://doi.org/10.1056/NEJMra0801644.CrossRefPubMed

16.

Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA Integration: molecular mechanisms and clinical implications. Viruses. 2017;9. https://doi.org/10.3390/v9040075.

17.

Likhitsup A, Lok AS. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. Clin Liver Dis. 2019;23:401–16. https://doi.org/10.1016/j.cld.2019.04.002.CrossRefPubMed

18.

Robinson WS, Miller RH, Marion PL. Hepadnaviruses and retroviruses share genome homology and features of replication. Hepatology. 1987;7:64S–73S. https://doi.org/10.1002/hep.1840070712.CrossRefPubMed

19.

McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. N Engl J Med. 2007;356:2614–21. https://doi.org/10.1056/NEJMoa067710.CrossRefPubMedPubMedCentral

20.

Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302–6. https://doi.org/10.1002/hep.510300525.CrossRefPubMed

21.

Wolters LMM, Niesters HGM, Hansen BE, van der Ende ME, Kroon FP, Richter C, et al. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort. J Clin Virol. 2002;24:173–81. https://doi.org/10.1016/s1386-6532(01)00245-1.CrossRefPubMed

22.

Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006;20:863–70. https://doi.org/10.1097/01.aids.0000218550.85081.59.CrossRefPubMed

23.

• Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2020. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. Accessed 2 July 2020. Important evidence-based guidelines on a variety of coinfections including HBV, aimed at clinicians involved in the care of PLWH.

24.

Lok ASF, McMahon BJ, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology. 2004;39:857–61. https://doi.org/10.1002/hep.20110.CrossRefPubMed

25.

Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatol. 2018;67:1560–99. https://doi.org/10.1002/hep.29800.CrossRef

26.

European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. https://doi.org/10.1016/j.jhep.2017.03.021.CrossRef

27.

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol International. 2016;10:1–98. https://doi.org/10.1007/s12072-015-9675-4.CrossRef

28.

Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, Sasadeusz J, et al. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals. AIDS. 2009;23:1707–15. https://doi.org/10.1097/QAD.0b013e32832b43f2.CrossRefPubMedPubMedCentral

29.

de Vries–Sluijs TEMS, Reijnders JGP, Hansen BE, Zaaijer HL, Prins JM, Pas SD, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology. 2010;139:1934–41. https://doi.org/10.1053/j.gastro.2010.08.045.CrossRef

30.

Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, et al. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLOS ONE. 2013;8:e68152. https://doi.org/10.1371/journal.pone.0068152.CrossRefPubMedPubMedCentral

31.

Matthews GV, Cooper DA, Dore GJ. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir. Antivir Ther (Lond). 2007;12:119–22.

32.

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–75. https://doi.org/10.1016/S0140-6736(12)61425-1.CrossRefPubMed

33.

Boyd A, Bottero J, Miailhes P, Lascoux-Combe C, Rougier H, Girard P-M, et al. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study. J Int AIDS Soc. 2017;20:21426. https://doi.org/10.7448/IAS.20.1.21426.CrossRefPubMedPubMedCentral

34.

Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, González-Lahoz J, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73–9. https://doi.org/10.1097/QAD.0b013e328340fde2.CrossRefPubMed

35.

Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444–53. https://doi.org/10.1002/hep.29320.CrossRefPubMed

36.

Lok ASF, McMahon BJ, Brown RS, Wong JB, Ahmed AT, Farah W, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63:284–306. https://doi.org/10.1002/hep.28280.CrossRefPubMed

37.

• Lo Re V, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, et al. Determinants of liver complications among HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr. 2019;82:71–80. https://doi.org/10.1097/QAI.0000000000002094One of the larger observational studies examining factors associated with ESLD and HCC specifically in HIV-HBV coinfection in the contemporary ART era; the strength of study is the use of validated clinical end points.CrossRefPubMedPubMedCentral

38.

Mallet V, Hamed K, Schwarzinger M. Prognosis of patients with chronic hepatitis B in France (2008–2013): a nationwide, observational and hospital-based study. J Hepatol. 2017;66:514–20. https://doi.org/10.1016/j.jhep.2016.10.031.CrossRefPubMed

39.

Lieveld FI, Smit C, Richter C, van Erpecum KJ, Spanier BWM, Gisolf EH, et al. Liver decompensation in HIV/hepatitis B coinfection in the combination antiretroviral therapy era does not seem increased compared to hepatitis B mono-infection. Liver Int. 2019;39:470–83. https://doi.org/10.1111/liv.14000.CrossRefPubMed

40.

• Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1–31. https://doi.org/10.15585/mmwr.rr6701a1This important report summarizes the current landscape of chronic HBV in the US, and updates recommendations around HBV prevention from the Advisory Committee on Immunization Practices and CDC.CrossRefPubMedPubMedCentral

41.

Centers of Disease Control. U.S. 2017 Surveillance data for viral hepatitis | CDC 2019. http://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm (accessed Jun 29, 2020).

42.

Falade-Nwulia O, Seaberg EC, Snider AE, Rinaldo CR, Phair J, Witt MD, et al. Incident hepatitis B virus infection in HIV-infected and HIV-uninfected men who have sex with men from pre-HAART to HAART periods: a cohort study. Ann Intern Med. 2015;163:673–80. https://doi.org/10.7326/M15-0547.CrossRefPubMedPubMedCentral

43.

Kushner T, Chen Z, Tressler S, Kaufman H, Feinberg J, Terrault NA. Trends in hepatitis B infection and immunity among women of childbearing age in the United States. Clin Infect Dis. 2019;71:586–92. https://doi.org/10.1093/cid/ciz841.CrossRefPubMedCentral

44.

Phinius BB, Anderson M, Bokete R, Mbangiwa T, Choga WT, Baruti K, et al. Incidence of hepatitis B virus infection among human immunodeficiency virus-infected treatment naïve adults in Botswana. Medicine (Baltimore). 2020;99:e19341. https://doi.org/10.1097/MD.0000000000019341.CrossRef

45.

Wirtz AL, Yeh PT, Flath NL, Beyrer C, Dolan K. HIV and viral hepatitis among imprisoned key populations. Epidemiol Rev. 2018;40:12–26. https://doi.org/10.1093/epirev/mxy003.CrossRefPubMedPubMedCentral

46.

• Weiser J, Perez A, Bradley H, King H, Shouse RL. Low prevalence of hepatitis B vaccination among patients receiving medical care for HIV infection in the United States, 2009 to 2012. Ann Intern Med. 2018;168:245–54. https://doi.org/10.7326/M17-1689A critical analysis of HBV vaccination practices from CDC’s Medical Monitoring Project, a surveillance system that aims to provide nationally representative, cross-sectional estimates of behavioral and clinical characteristics of HIV-positive adults in the US.CrossRefPubMed

47.

Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017;167:794–804. https://doi.org/10.7326/M17-1106.CrossRefPubMed

48.

Shilaih M, Marzel A, Scherrer AU, Braun DL, Kovari H, Rougemont M, et al. Dually active HIV/HBV antiretrovirals as protection against incident hepatitis B infections: potential for prophylaxis. J Infect Dis. 2016;214:599–606. https://doi.org/10.1093/infdis/jiw195.CrossRefPubMed

49.

Lee J-H, Hong S, Im JH, Lee J-S, Baek JH, Kwon HY. Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. Vaccine. 2020;38:3995–4000. https://doi.org/10.1016/j.vaccine.2020.04.022.CrossRefPubMed

50.

Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. Vaccine. 2012;30:2556–63. https://doi.org/10.1016/j.vaccine.2012.01.087.CrossRefPubMed

51.

Janssen JM, Jackson S, Heyward WL, Janssen RS. Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18-70 years of age. Vaccine. 2015;33:3614–8. https://doi.org/10.1016/j.vaccine.2015.05.070.CrossRefPubMed

52.

Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018;36:668–74. https://doi.org/10.1016/j.vaccine.2017.12.038.CrossRefPubMed

53.

Yip TC-F, Lok AS-F. How do we determine whether a functional cure for HBV infection has been achieved? Clin Gastroenterol Hepatol. 2020;18:548–50. https://doi.org/10.1016/j.cgh.2019.08.033.CrossRefPubMed

54.

Yeo YH, Ho HJ, Yang H-I, Tseng T-C, Hosaka T, Trinh HN, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156:635–646.e9. https://doi.org/10.1053/j.gastro.2018.10.027.CrossRefPubMed

55.

Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic HBV infection: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020. https://doi.org/10.1016/j.cgh.2020.05.041.

56.

Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS. 2017;31:2035–52. https://doi.org/10.1097/QAD.0000000000001574.CrossRefPubMedPubMedCentral

57.

Matthews GV, Ali RJ, Avihingsanon A, Amin J, Hammond R, Bowden S, et al. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals. PLoS One. 2013;8:e61297. https://doi.org/10.1371/journal.pone.0061297.CrossRefPubMedPubMedCentral

58.

Zoutendijk R, Zaaijer HL, de Vries-Sluijs TEMS, Reijnders JGP, Mulder JW, Kroon FP, et al. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis. 2012;206:974–80. https://doi.org/10.1093/infdis/jis439.CrossRefPubMed

59.

Chihota BV, Wandeler G, Chilengi R, Mulenga L, Chung RT, Bhattacharya D, et al. High rates of hepatitis B virus (HBV) functional cure among human immunodeficiency virus-HBV coinfected patients on antiretroviral therapy in Zambia. J Infect Dis. 2020;221:218–22. https://doi.org/10.1093/infdis/jiz450.CrossRefPubMed

60.

Huang Y-S, Sun H-Y, Chang S-Y, Chuang Y-C, Cheng A, Huang S-H, et al. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection. Hepatol Int. 2019;13:431–9. https://doi.org/10.1007/s12072-019-09953-4.CrossRefPubMed

61.

Jaroszewicz J, Reiberger T, Meyer-Olson D, Mauss S, Vogel M, Ingiliz P, et al. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PLoS One. 2012;7:e43143. https://doi.org/10.1371/journal.pone.0043143.CrossRefPubMedPubMedCentral

62.

Boyd A, Gozlan J, Miailhes P, Lascoux-Combe C, Cam MS-L, Rougier H, et al. Rates and determinants of hepatitis B “e” antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus. AIDS. 2015;29:1963–73. https://doi.org/10.1097/QAD.0000000000000795.CrossRefPubMed

63.

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (accessed Jul 3, 2020).

64.

Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, et al. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016;43:621–30. https://doi.org/10.1111/apt.13505.CrossRefPubMedPubMedCentral

65.

Ghany MG. Current treatment guidelines of chronic hepatitis B: the role of nucleos(t)ide analogues and peginterferon. Best Pract Res Clin Gastroenterol. 2017;31:299–309. https://doi.org/10.1016/j.bpg.2017.04.012.CrossRefPubMed

66.

Li J, Gordon SC, Rupp LB, Zhang T, Boscarino JA, Vijayadeva V, et al. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21:930–7. https://doi.org/10.1111/jvh.12224.CrossRefPubMed

67.

Kim WR, Berg T, Asselah T, Flisiak R, Fung S, Gordon SC, et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773–80. https://doi.org/10.1016/j.jhep.2015.11.012.CrossRefPubMed

68.

Sterling RK, King WC, Wahed AS, Kleiner DE, Khalili M, Sulkowski M, et al. Evaluating noninvasive markers to identify advanced fibrosis by liver biopsy in HBV/HIV co-infected adults. Hepatology. 2020;71:411–21. https://doi.org/10.1002/hep.30825.CrossRefPubMed

69.

Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014;28:881–90. https://doi.org/10.1097/QAD.0000000000000163.CrossRefPubMedPubMedCentral

70.

Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer. 2012;118:6226–33. https://doi.org/10.1002/cncr.27694.CrossRefPubMedPubMedCentral

71.

Engels EA, Yanik EL, Wheeler W, Gill MJ, Shiels MS, Dubrow R, et al. Cancer-attributable mortality among people with treated human immunodeficiency virus infection in North America. Clin Infect Dis. 2017;65:636–43. https://doi.org/10.1093/cid/cix392.CrossRefPubMedPubMedCentral

72.

Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007;47:527–37. https://doi.org/10.1016/j.jhep.2007.06.010.CrossRefPubMed

73.

Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist. 2011;16:1258–69. https://doi.org/10.1634/theoncologist.2010-0400.CrossRefPubMedPubMedCentral

74.

Torgersen J, Kallan MJ, Carbonari DM, Park LS, Mehta RL, D’Addeo K, et al. HIV RNA, CD4+ percentage, and risk of hepatocellular carcinoma by cirrhosis status. J Natl Cancer Inst. 2019;112:747–55. https://doi.org/10.1093/jnci/djz214.CrossRefPubMedCentral

75.

Lin C-L, Kao J-H. Risk stratification for hepatitis B virus related hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28:10–7. https://doi.org/10.1111/jgh.12010.CrossRefPubMed

76.

Merchante N, Rodríguez-Fernández M, Pineda JA. Screening for hepatocellular carcinoma in HIV-infected patients: current evidence and controversies. Curr HIV/AIDS Rep. 2020;17:6–17. https://doi.org/10.1007/s11904-019-00475-0.CrossRefPubMed

Title: Chronic Hepatitis B and HIV Coinfection: a Continuing Challenge in the Era of Antiretroviral Therapy
Author: H. Nina Kim
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Hepatitis B
Tenofovir
Human Immunodeficiency Virus
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Current Hepatology Reports / Issue 4/2020
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-020-00541-x

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2020

Alcohol Consumption in Non-Alcoholic Fatty Liver Disease: Safety and Disease Overlap

Correction to: Hepatitis B Core Antibody: Role in Clinical Practice in 2020

High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression

National and Global Ethnicity Differences in Non-alcoholic Fatty Liver Disease

Spontaneous Bacterial Peritonitis and Secondary Bacterial Peritonitis—a Comprehensive Review

A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage